PUBLIC COMPANY
saveTARSUS
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800MAlkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”biopharma_dive · 1h ago
- Tarsus bets $450M on Alkeus’ Stargardt drugTo broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies said Thursday morning. It's the l…endpoints · 6h ago
- Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drugTarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.fiercebiotech · 9h ago
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.biopharma_dive · 27d ago
- Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfrontPlus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...endpoints · 28d ago
comments(0)
5-min edit window · permanent after that